Literature DB >> 8463044

Natural history of cervical intraepithelial neoplasia: a critical review.

A G Ostör1.   

Abstract

The literature dealing with the natural history of cervical intraepithelial neoplasia (CIN) since 1950 is reviewed, in particular from the viewpoint of regression, persistence, and progression. When stratified into the various grades of severity, the composite data indicate the approximate likelihood of regression of CIN 1 is 60%, persistence 30%, progression to CIN 3 10%, and progression to invasion 1%. The corresponding approximations for CIN 2 are 40%, 40%, 20%, and 5%, respectively. The likelihood of CIN 3 regressing is 33% and progressing to invasion greater than 12%. It is obvious from the above figures that the probability of an atypical epithelium becoming invasive increases with the severity of the atypia, but does not occur in every case. Even the higher degrees of atypia may regress in a significant proportion of cases. As morphology by itself does not predict which lesion will progress or regress, future efforts should seek factors other than morphological to determine the prognosis in individual patients.

Entities:  

Mesh:

Year:  1993        PMID: 8463044

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  234 in total

1.  Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix.

Authors:  C J de Boer; E van Dorst; H van Krieken; C M Jansen-van Rhijn; S O Warnaar; G J Fleuren; S V Litvinov
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Effectiveness of follow up-letters to health care providers in triggering follow-up for women with abnormal results on Papanicolaou testing.

Authors:  E Wagner; M A Duggan
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

3.  Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay.

Authors:  I Nindl; B Lotz; R Kühne-Heid; U Endisch; A Schneider
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

4.  Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia.

Authors:  Divya A Patel; Laura S Rozek; Justin A Colacino; Adrienne Van Zomeren-Dohm; Mack T Ruffin; Elizabeth R Unger; Dana C Dolinoy; David C Swan; Juanita Onyekwuluje; Cecilia R DeGraffinreid; Electra D Paskett
Journal:  J Virol Methods       Date:  2012-06-01       Impact factor: 2.014

Review 5.  How can we develop a cost-effective quality cervical screening programme?

Authors:  Sue Wilson; Helen Lester
Journal:  Br J Gen Pract       Date:  2002-06       Impact factor: 5.386

Review 6.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

7.  High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic women of eastern Uttar Pradesh, India: a population-based study.

Authors:  Shikha Srivastava; Sadhana Gupta; Jagat Kumar Roy
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

8.  Cervical cancer pathogenesis is associated with one-carbon metabolism.

Authors:  Sujata Pathak; Neerja Bhatla; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2012-06-23       Impact factor: 3.396

9.  Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort.

Authors:  Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

10.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.